Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WS204 is a potent and selective small molecule antagonist of the Transient Receptor Potential Canonical 4 (TRPC4) channel. Identified through high-throughput screening, it exhibits high selectivity for TRPC4 over other members of the TRPC family, including TRPC1, TRPC3, TRPC5, and TRPC6, as well as other TRP channels such as TRPV1 and TRPM8. By blocking TRPC4-mediated calcium entry, WS204 serves as a critical pharmacological tool for investigating the physiological and pathological roles of TRPC4 in various tissues, including smooth muscle contraction, neurotransmission, and vascular function. While primarily used as a research reagent, TRPC4 inhibition has been explored preclinically for potential therapeutic applications in treating anxiety, depression, and certain cardiovascular conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WS204.